Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medincell's quarterly cash, cash equivalents, marketable securities
declined
from Mar. 2025 ($77.73 Mil) to Sep. 2025 ($62.80 Mil) but then
increased
from Sep. 2025 ($62.80 Mil) to Mar. 2026 ($98.06 Mil).
Medincell's annual cash, cash equivalents, marketable securities
increased
from Mar. 2024 ($21.15 Mil) to Mar. 2025 ($77.73 Mil) and
increased
from Mar. 2025 ($77.73 Mil) to Mar. 2026 ($98.06 Mil).
Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Medincell Cash, Cash Equivalents, Marketable Securities Related Terms
Medincell Cash, Cash Equivalents, Marketable Securities Historical Data
* Premium members only.
The historical data trend for Medincell's Cash, Cash Equivalents, Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
What does a Cash, Cash Equivalents, Marketable Securities of $98.06 Mil mean?
Medincell (MDCLF) has a Cash, Cash Equivalents, Marketable Securities of $98.06 Mil as of Mar. 2026. The total cash, cash equivalents and marketable securities a company has on hand. View historical data on Medincell and its competitors.
Is Medincell's Cash, Cash Equivalents, Marketable Securities too high?
Medincell's current Cash, Cash Equivalents, Marketable Securities is $98.06 Mil. Overall, Medincell has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's Cash, Cash Equivalents, Marketable Securities compare to VRTX and REGN?
Medincell's Cash, Cash Equivalents, Marketable Securities of $98.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash, Cash Equivalents, Marketable Securities for a Biotechnology company?
A good Cash, Cash Equivalents, Marketable Securities depends on the Biotechnology industry context. However, Cash, Cash Equivalents, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash, Cash Equivalents, Marketable Securities mean?
A high Cash, Cash Equivalents, Marketable Securities can signal that a stock is expensive relative to its fundamentals. The total cash, cash equivalents and marketable securities a company has on hand. View historical data on Medincell and its competitors. Medincell's current Cash, Cash Equivalents, Marketable Securities is $98.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current Cash, Cash Equivalents, Marketable Securities of $98.06 Mil. The stock's GF Value™ is $30.25, compared to a current price of $34.39 — trading 13.7% above its estimated fair value. The current Cash, Cash Equivalents, Marketable Securities is $98.06 Mil. Medincell's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash, Cash Equivalents, Marketable Securities calculated?
Cash, Cash Equivalents, Marketable Securities is calculated from a company's financial statements. For Medincell (MDCLF), the current Cash, Cash Equivalents, Marketable Securities is $98.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (MDCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be overvalued.
The current stock price of $34.39 is trading 13.7% above its estimated GF Value™ of $30.25.
Key valuation signals for MDCLF:
Cash, Cash Equivalents, Marketable Securities: $98.06 Mil
GF Value™: $30.25 vs. price of $34.39 (13.7% above fair value)
No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
78GF Score
Get the complete analysis for MDCLF
Cash, Cash Equivalents, Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDCLF has been successfully added to your 
